Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2019
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALA-3000,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose Phase 1 Study of ALA-3000
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 11, 2025
Lead Product(s) : ALA-3000,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YZJ-1139,Escitalopram Oxalate
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2024
Lead Product(s) : YZJ-1139,Escitalopram Oxalate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Electroacupuncture on Treating the First-episode Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction i...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Escitalopram Oxalate,Sulforaphane
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2021
Lead Product(s) : Escitalopram Oxalate,Sulforaphane
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Escitalopram Oxalate,Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan |
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2021
Lead Product(s) : Escitalopram Oxalate,Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan |
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : National Institute on Aging
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2021
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : National Institute on Aging
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Citalopram Hydrobromide,Escitalopram Oxalate,Fluoxetine Hydrochloride,Paroxetine Hydrochloride,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2021
Lead Product(s) : Citalopram Hydrobromide,Escitalopram Oxalate,Fluoxetine Hydrochloride,Paroxetine Hydrochloride,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Ybrain Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Self-administered tDCS in Patients With MDD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2020
Lead Product(s) : Escitalopram Oxalate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Ybrain Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable